Please select a Capability in order to start your service request.
Combined Technologies from BD, CareFusion Create End-to-End IV ManagementDec 7, 2015
FRANKLIN LAKES, N.J., Dec. 7, 2015 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today introduced a simplified way for hospitals to manage intravenous (IV) medication to help improve safety and reduce waste.
National data show that 90 percent of hospital patients receive an IV medication during their stay1. However, a manual IV compounding process is prone to errors, with an average error rate of 9 percent for chemotherapy, injectables and total parenteral nutrition (TPN) infusions2. In addition, 7 percent to 15 percent of oncology budgets are spent on infusions that are prepared, but never get used3, resulting in unnecessary waste.
During the 50th Annual American Society of Health-system Pharmacists (ASHP) Midyear Clinical Meeting being held Dec. 6-10 in New Orleans BD introduced a new, automated IV management solution built on the combined technologies of BD and CareFusion, which BD acquired in March. This is the first solution to include BD and CareFusion technologies working together to create a simplified and safer medication management system.
“Combining BD and CareFusion technologies creates a safer and more simplified way to manage IV medication at hospitals,” said Ranjeet Banerjee, worldwide president of Medication Management Solutions for BD. “We will continue to integrate and innovate to develop medication management solutions that help clinicians deliver the safest and most efficient care.”
How it works:
The unique end-to-end IV management process on display at booth #2339 demonstrates a cohesive approach to reducing the opportunities for human error, protecting health care workers from occupational hazards and increasing efficiency to enable nurses and pharmacists to spend more time with patients. For more information please visit: http://www.bd.com/ashp.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.